ask why
Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

The papers that matter: 9 November to 15 November 2026

The 10 most important of the 41 papers published that week and summarised on Y, ranked by what verified readers said would change practice, then by strength of design and size. Secondary analyses come last.
Oncology · Breast Cancer Res Treat · 2026-11-14

Meta-analysis of 7 randomised contrasts (2,627 participants) in non-metastatic TNBC: adding carboplatin to comparable chemotherapy improved disease control (HR 0.779) and pCR (OR 2.04), but overall survival benefit was not established (HR 0.810, p=0.107).

Meta-analysisn = 2,627
Wu et al. Survival benefit of adding carboplatin to standard anthracycline-taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysis
Urology · World J Urol · 2026-11-15

Meta-analysis of 2 RCTs (606 randomised, 590 analysed) in non-muscle-invasive bladder cancer: urinary biomarker-guided surveillance cut cystoscopy use by 55.8–74.9% vs standard cystoscopy, with no significant difference in recurrence (RR 1.04); non-inferiority not established.

Meta-analysisn = 606
Abushamma et al. Urinary biomarker-guided surveillance versus standard cystoscopic surveillance for non-muscle-invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trials

Previous weekNext weekAll weeks

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.